What Arch Therapeutics does

Arch Therapeutics, Inc. is a publicly traded medical device company (OTCQB: ARTH) headquartered in Framingham, Massachusetts, that develops and commercializes wound care and biosurgical products based on a proprietary self-assembling peptide (SAP) platform technology. The technology, discovered at MIT by co-founder Dr. Rutledge Ellis-Behnke, uses synthetic peptides composed of naturally-occurring amino acids that, upon contact with ionic wound fluid, self-assemble into a nanofiber network mimicking the extracellular matrix. This forms an immediate physical barrier that provides hemostasis without pressure, cauterization, vasoconstriction, coagulation, or cross-linked adhesives, while serving as a scaffold to facilitate tissue repair. The company's primary commercial product is AC5 Advanced Wound System, marketed in the USA for chronic and acute wound care, with a parallel European product, AC5 Topical Hemostat, sold for hemostatic and sealant applications.

Name

Arch Therapeutics

Legal name

Arch Therapeutics, Inc.

Website

https://archtherapeutics.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Arch Therapeutics is a publicly traded medical device company that develops and sells the AC5 Advanced Wound System, a synthetic self-assembling peptide wound dressing for hospitals, wound care centers, and plastic surgery practices, plus AC5 Topical Hemostat in Europe.

Ownership category

akta.pro rank

Product category

Wound Care and Hemostatic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Wound care products
• Hemostatic devices
• Self-assembling peptides
• Biosurgical products
• Medical device manufacturing

Headquarters

HQ city

Natick

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. AC5 Advanced Wound System Sales: Direct product sales of AC5 Advanced Wound System (item number AC5-1001) available in the USA. The company sells directly to government and non-government customers through phone and email ordering channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Arch Therapeutics develops and commercializes self-assembling peptide (SAP) based wound care and biosurgical products. Its flagship product, AC5 Advanced Wound System, is a synthetic peptide matrix composed of naturally-occurring amino acids that forms a nanofiber network barrier on contact with wound ionic charge, providing hemostasis, modulating inflammation, and serving as a scaffold for tissue regeneration. The company also markets AC5 Topical Hemostat in Europe for hemostatic and sealant surgical applications.

Product overview

Arch Therapeutics offers a unified platform of self-assembling peptide (SAP) products under the AC5 family. The core technology is a synthetic peptide matrix composed of naturally-occurring amino acids that self-assembles into a nanofiber network upon contact with ionic wound fluid. In the USA, this technology is marketed as the AC5 Advanced Wound System, an advanced wound dressing for chronic and acute wound care. In Europe, the same technology is sold as AC5 Topical Hemostat for hemostatic and sealant applications. Both products leverage the same proprietary self-assembling peptide platform to provide immediate barrier formation, hemostasis, and a microenvironment conducive to normal wound healing without requiring cold chain storage.

Differentiator

Problem solved

Functional benefit

Brands

• AC5 Advanced Wound System: The company's primary commercial wound care product - a synthetic self-assembling peptide matrix that forms a nanofiber barrier on wounds to provide hemostasis and facilitate tissue healing. Available in the USA.
• AC5 Topical Hemostat

Products and services

• AC5 Advanced Wound System A synthetic self-assembling peptide-based advanced wound dressing (item number AC5-1001) that forms a nanofiber network upon contact with wound fluid, providing a physical barrier, modulating inflammation, and serving as a scaffold for tissue regeneration. Available in the USA for hospitals, wound care centers, plastic surgery practices, and vascular surgery departments managing chronic or acute wounds including venous leg ulcers, burn wounds, decubitus ulcers, and surgical wounds.
• AC5 Topical Hemostat The same synthetic self-assembling peptide technology as AC5 Advanced Wound System, marketed in Europe as a topical hemostat for promoting hemostasis and acting as a surgical sealant during interventional procedures, surgery, trauma, colonoscopy biopsy, and device implantation.

Quantifiable outcome

• 41% statistically significant improvement in median time to hemostasis (TTH) with AC5 vs control; TTH ≤30 seconds in AC5-treated wounds including patients on antiplatelet therapy
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Integra LifeSciences: Integra LifeSciences is a focused medical device company with a substantial wound care, regenerative tissue, and surgical franchise (e.g., Integra Dermal Regeneration Template). Comparable to Arch given the overlapping regenerative medicine and advanced wound care positioning, and similar mid-cap specialty medical device profile.
• ConvaTec: ConvaTec is a focused wound care and ostomy company with advanced wound dressings sold to hospitals, wound care clinics, and home health. Comparable to Arch's AC5 Advanced Wound System given the same advanced wound care customer base and clinical positioning.
• Organogenesis: Organogenesis is a regenerative medicine company selling skin substitutes and advanced wound care products (e.g., Apligraf, Dermagraft) into wound care centers and hospitals. Closely comparable to Arch given the shared regenerative/biologic-matrix positioning in advanced wound healing and a similar specialty commercial footprint.
• Collagen Solutions: Collagen Solutions/Collagen Matrix produces collagen-based medical devices including hemostats and wound care products. Directly comparable to Arch given the shared regenerative/biomaterial positioning for hemostasis and tissue repair in surgical and wound care applications.

Broad incumbents

• 3M Health Care: 3M's Health Care segment provides advanced wound care products (e.g., 3M Tegaderm) sold globally to hospitals and clinics. Comparable to Arch given the shared advanced wound care customer base, though 3M is a much larger diversified incumbent.
• BD (Becton Dickinson): BD offers hemostatic agents and surgical sealants through its surgery and biosciences portfolio, including products addressing bleeding control in the OR. Comparable to Arch's AC5 as both compete in surgical hemostasis with hospital customers and share a similar evidence-driven commercial model.
• Smith+Nephew: Smith+Nephew is a global medical device leader in advanced wound management (e.g., PICO, ALLEVYN) and surgical devices. Directly comparable to Arch's AC5 Advanced Wound System given its position in advanced wound dressings and chronic wound management sold to hospitals and wound care centers.
• Johnson & Johnson (Ethicon): Ethicon, a J&J company, markets SURGICEL, EVICEL, and other hemostatic and sealant products used in operating rooms worldwide. Closely comparable to Arch's surgical hemostasis/barrier franchise given overlapping target customers (surgeons, hospitals) and product categories (topical hemostats and sealants).
• Baxter International: Baxter is a major incumbent in hemostats and sealants through its FLOSEAL, TISSEEL, and COSEAL products used in surgical settings. Directly comparable to Arch's AC5 Topical Hemostat product given shared positioning in surgical hemostasis and tissue sealing across multiple surgical specialties.

Emerging players

• ZymoGenetics (acquired by Bristol-Myers Squibb): ZymoGenetics historically developed topical recombinant thrombin (RECOTHROM) as a surgical hemostat. Comparable to Arch given the shared topical hemostat positioning for surgical bleeding control, and represents a comparable specialty hemostat strategic story (eventually acquired by a large pharma).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ARTHinc
• LinkedInlinkedin.com/company/arch-therapeutics-inc
• Facebookfacebook.com/ArchTherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds11 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arch Therapeutics